Citing “usually well-informed sources,” the Financial Times reports that Shire is considering a $4 billion bid for rare disease specialist NPS Pharma, a deal that would bolster the company’s last blockbuster acquisition and perhaps get it out of rivals’ crosshairs.

…read more

Source: Buzz: Shire eyes NPS for $4B amid an M&A blitz